Evidence map›Paper›PMID 36291827›Full record

ArticleCancers2022

Molecularly Targeted Photothermal Ablation of Epidermal Growth Factor Receptor-Expressing Cancer Cells with a Polypyrrole-Iron Oxide-Afatinib Nanocomposite.

Lekshmi Rethi, Chinmaya Mutalik, Lekha Rethi, Wei-Hung Chiang, Hsin-Lun Lee, Wen-Yu Pan, Tze-Sen Yang, Jeng-Fong Chiou, Yin-Ju Chen, Er-Yuan Chuang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Nanotoxicology: developments and new insights.Nanomedicine (London, England) · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of functional biomaterials · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lekshmi RethiInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Chinmaya MutalikInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-5548-2260
Lekha RethiInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-8030-3137
Wei-Hung ChiangDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan.ORCID 0000-0002-6350-6696
Hsin-Lun LeeDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
Wen-Yu PanSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Tze-Sen YangGraduate Institute of Biomedical Opto Mechatronics, Taipei Medical University, Taipei 11031, Taiwan.
Jeng-Fong ChiouDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.
Yin-Ju ChenInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-9516-9463
Er-Yuan ChuangInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-1593-4573
Long-Sheng LuInternational Ph.D. Program in Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-4247-1981
Taipei Medical University · TWTaipei Medical University Hospital · TWNational Taiwan University of Science and Technology · TWWan Fang Hospital · TW

Funding

Ministry of Education DP2-110-21121-03-C-06-01, DP2-110-21121-03-C-06-02, DP2-110-21121-03-C-06-03, DP2-109-21121-03-C-06-01, DP2-109-21121-03-C-06-02, DP2-109-21121-03-C-06-03Ministry of Science and Technology MOST-110-2320-B-038-056, MOST-110-2314-B-038-138, MOST-109-2314-B-038-122, MOST-109-2314-B-038-141, MOST-109-2635-B-038-001, MOST-109-2314-B-038-072, MOST 106-2320-B-038-03Ministry of Science and Technology MOST-111-2320-B-038-039National Health Research Institutes NHRI-EX109- 10713EITaipei Medical University TMU105-AE1-B13
6 · The paper itself

Abstract

Near-infrared-photothermal therapy (NIR-PTT) is a potential modality for cancer treatment. Directing photothermal effects specifically to cancer cells may enhance the therapeutic index for the best treatment outcome. While epithelial growth factor receptor (EGFR) is commonly overexpressed/genetically altered in human malignancy, it remains unknown whether targeting EGFR with tyrosine kinase inhibitor (TKI)-conjugated nanoparticles may direct NIR-PTT to cancers with cellular precision. In the present study, we tested this possibility through the fabrication of a polypyrrole-iron oxide-afatinib nanocomposite (PIA-NC). In the PIA-NC, a biocompatible and photothermally conductive polymer (polypyrrole) was conjugated to a TKI (afatinib) that binds to overexpressed wild-type EGFR without overt cytotoxicity. A Fenton catalyst (iron oxide) was further encapsulated in the NC to drive the intracellular ROS surge upon heat activation. Diverse physical and chemical characterization experiments were conducted. Particle internalization, cytotoxicity, ROS production, and apoptosis in EGFR-positive and -negative cell lines were investigated in the presence and absence of NIR. We found that the PIA-NCs were stable with a size of 243 nm and a zeta potential of +35 mV. These PIA-NCs were readily internalized close to the cell membrane by all types of cells used in the study. The Fourier transform infrared spectra showed 3295 cm

Indexed as

afatinibEGFRiron oxidephotothermal therapypolypyrrole

Identifiers

PMID36291827
PMCPMC9599920
OpenAlexW4306366860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.